Carbohydrates—namely glycans—decorate every cell in the human body and most secreted
proteins. Advances in genomics, glycoproteomics and tools from chemical biology have …

Decades of research have disclosed a plethora of alterations in protein glycosylation that
decisively impact in all stages of disease and ultimately contribute to more aggressive cell …

Currently approved immune checkpoint inhibitor therapies targeting the PD-1 and CTLA-4
receptor pathways are powerful treatment options for certain cancers; however, most …

Simple Summary All cells are covered in a thick layer of sugar molecules known as glycans.
Changes to this sugar coat are common in cancer, and in particular cancer cells often …

Cell surface sialosides constitute a central axis of immune modulation that is exploited by
tumors to evade both innate and adaptive immune destruction. Therapeutic strategies that …

First-generation immune checkpoint inhibitors, including anti–CTLA-4 and anti–programmed
death 1 (anti–PD-1) antibodies, have led to major clinical progress, yet resistance frequently …

Cancer immunotherapy in the form of immune checkpoint inhibitors and cellular therapies
has improved the treatment and prognosis of many patients. Nevertheless, most cancers are …

The increase of cell surface sialic acid is a characteristic shared by many tumor types. A
correlation between hypersialylation and immunoprotection has been observed, but few …

Sialic acid sugar-carrying glycans, sialoglycans, are aberrantly expressed on many tumor
cells and have emerged as potent regulatory molecules involved in creating a tumor …

Alteration of the surface glycosylation pattern on malignant cells potentially affects tumor
immunity by directly influencing interactions with glycan-binding proteins (lectins) on the …